G1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2024 Earnings Call Transcript

Jack Bailey: Sure. Yeah. I can give you an outline of that. So about 90% of our used today is in the first-line setting, about 10% is in second line plus. Within that 10% is the result of topotecan patients which is part of our indication as well as patients who are re-challenged with the toposite platinum our overall market share or our first line market share is around 13%. Our overall market share, or our first-line market share, is around 13%. Our overall market share is not too different from that, and our share in the second-line setting is not too different from that either, sampling double-digits of eligible patients in the second-line setting. So there’s not a huge difference in our market share across first- and second-line use. Our focus is mainly first-line use because that represents the majority of patients.

Unidentified Analyst: Very helpful. Thank you.

Operator: Thank you. There are no further questions in the queue. I’d like to turn it back over to Jack Bailey, CEO for any closing remarks.

Jack Bailey: Thank you, operator. As always, we look forward to keeping everybody updated on our progress. Certainly, thank you for joining us today and we’ll be in touch.

Operator: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect, everyone have a great day.